Home » Newsletters » BioWorld Science

BioWorld Science

July 16, 2009

View Archived Issues

MurA transferase inhibitors as antibacterial agents claimed by MaxThera

GE Healthcare patents novel contrast agents

Dimebon and donepezil combination found safe and well tolerated in Alzheimer's disease patients

Pharmacokinetic/pharmacodynamic data on PF-3084014 lead to discontinuation in AD

Novel vitamin D3 analogue ZK-203278 a potent immunomodulator

Keryx commences phase I KRX-0401 study in recurrent pediatric solid tumors

FDA accepts for filing and designates priority review to Cadence's NDA for Acetavance

Emergensys acquires Spencer Pharmaceutical in reverse merger transaction

Rexahn and Korea Research Institute of Chemical Technology sign licensing partnership

Abbott and GSK to develop automated molecular diagnostic test for MAGE-A3 antigen

BioMarin completes patient enrollment in phase I/II clinical trial of BMN-110 in MPS IVA

Johnson & Johnson reports 2009 second-quarter results

7-Isopentenyloxycoumarin has neuroprotective effects in vivo

cGMP inhibition observed in cerebrospinal fluid with PF-04447943 in humans

Wyeth's Prevenar 13 pneumococcal vaccine approved in Chile

Caduet approved in Japan for hypertension and hypercholesterolemia

Noven presents phase II results for Mesafem non-hormonal vasomotor therapy

Maxygen reports results from phase IIa MAXY-G34 study in breast cancer

Clinuvel reports phase II results for afamelanotide in solar urticaria

Ortho-McNeil provides update on rivaroxaban complete response letter from the FDA

Xoma releases results from phase I XOMA-052 trial in type 2 diabetes

Schering-Plough expands vicriviroc phase II study in treatment-naive HIV

FDA grants fast track status to Shire's velaglucerase alfa for Type I Gaucher disease

Targacept reports results from phase IIb trial of TC-5214 as an add-on treatment for MDD